CytomX Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -48.85 | -100% |
| P/S |
|
1.05 | 33.76 | -96.89% |
|
|
| P/BV |
|
-2.24 | 4.82 | -146.47% |
|
|
| P/FCF |
|
-1.73 | 61 | -102.83% |
|
|
| Ev/Ebitda |
|
-23.92 | -22.15 | 8% |
|
|
| Ev/S |
|
1.02 | 22.56 | -95.49% |
|
|
| Ev/FCF |
|
-1.81 | 68.78 | -102.64% |
|
|
| E/P |
|
-0.0058 | 0.0178 | -132.63% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-4.26 | 4.98 | -185.54% | -109.89 | -96.13% |
| ROE |
|
1.2 | 9.61 | -87.52% |
|
|
| ROA |
|
-0.2774 | 0.3443 | -180.57% |
|
|
| ROIC |
|
-71.16 | 7.63 | -1032.1% |
|
|
| ROS |
|
-0.5622 | -25.17 | -97.77% |
|
|
| ROCE |
|
13.67 | 15.35 | -10.97% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-3.24 | -3.68 | -11.77% | -2.04 | +59.29% |
| Nеt Debt/Ebitda |
|
0.7419 | -3.44 | -121.59% |
|
|
| Debt/Ratio |
|
0.0681 | 0.1985 | -65.68% |
|
|
| Debt/Equity |
|
2.33 | 1.66 | 40.11% |
|
|
| Debt/Net Income |
|
-24.56 | 10.32 | -337.89% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5442 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2237 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9889 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4952 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5442 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
8/10
|
76.02 | -56.89 | -233.63% | ||
| Growth impulse Ebitda in 5 years |
|
-96.11 | -54.68 | 75.77% | ||
| Growth impulse Net Income in 5 years |
|
-99.44 | -58.33 | 70.48% | ||
| Growth impulse FCF in 5 years |
|
-60.5 | -49.48 | 22.27% | ||
| Growth impulse EPS in 5 years |
|
-99.66 | -32.41 | 207.5% |
IP Score
3.26/10
